Loading
Latest filing published 15 Apr 2026 for 동성제약, €18.3M.
Based on 4 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
유암코제약산업제1호기업재무안정사모투자 appears in our data through filings on 동성제약 shares, published by DART (FSS). Over a trading history stretching from 31 March 2026 to 9 April 2026, the count stands at 4 filings.
On the market, this insider has only ever bought: 4 purchases, €103.4M in total. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket.
In size, the median ticket on the buying side is €23.1M. Scaled by market value, the purchases weigh a median 23.9% of market cap (sample: 4 purchases). On 3 out of 4 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. For 4 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 0% of cases, with a median move of +0.0%. These figures describe past trades and do not predict future prices.
The newest entry dates from 15 April 2026: an open-market purchase of €18.3M, in 동성제약. Filings reach the DART (FSS) feed a median of 6 days after the trade. Until a filing is published, the market cannot know about the trade. Source: insider filings from DART (FSS). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations